We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer
Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient
Climate change helps the spread of infectious diseases. Plus: rise in fungal infections highlights risks of antimicrobial resistance; Sydney shows how to almost eliminate HIV transmission; wait goes on for effective Long Covid treatments
At least three descendants of Omicron have scientists on alert and vaccination programmes speeding up
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
Preliminary studies find exposure to prevalent XBB.1.5 strain elicits antibodies to BA.2.86
Potential mutations prompts authorities to begin immunisation rollout in September
As vaccines are tweaked while new sub-variants emerge, the virus cannot be treated yet as a seasonal bug
Prominent figure in UK pandemic response becomes medical consultant at pharma group
New vaccines centre supports aim to develop jab for any new potential killer pathogen within 100 days
Move by RMT, Unite and Aslef comes as stoppage by top NHS doctors in England ends without resolution
A doctor, a model and a boxer raised millions from Covid sceptics and anti-vaxxers. Then a knock-down, drag-out brawl broke out
New treatments have had remarkable results but there are reasons to be cautious
Experts are waking up to the threat posed by artificial intelligence programmes if they fall into malevolent hands
Pharmaceuticals producer in first court hearing on Monday
Healthcare groups call for reforms to pharma supply chains as up to half a million patients could be affected
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
US biotech group is among coronavirus vaccine makers struggling with reduced demand post-pandemic
From India to Britain, we have always managed to get in the way of our own inventiveness
A demonised elite produced vaccines and furloughs while a supposedly rebellious public mostly followed the rules
Noubar Afeyan says court rulings on abortion pills and access to healthcare undermine efforts to combat diseases
European health officials have advocated portfolio diversity to help fight different variants
Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects
Revamp that would cut drugmakers’ years of market exclusivity meets fierce opposition from sector
Proposal for compulsory licensing risks ire of pharma groups keen to protect patents and revenue
International Edition
